Chemoradiation for Locoregionally Advanced Laryngeal Cancer

Andréanne Leblanc; Toms Vengaloor Thomas; Nathaniel Bouganim

doi:10.1016/j.otc.2022.12.004

Chemoradiation for Locoregionally Advanced Laryngeal Cancer

Otolaryngol Clin North Am. 2023 Apr;56(2):285-293. doi: 10.1016/j.otc.2022.12.004.

Authors

Andréanne Leblanc¹, Toms Vengaloor Thomas², Nathaniel Bouganim³

Affiliations

¹ Medical Oncology, Royal Victoria Hospital/Cedars Cancer Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada. Electronic address: andreanne.leblanc@mail.mcgill.ca.
² Dept of Radiation Oncology, University of Mississippi Medical Center, 2500 North State street, Jackson, MS, 39216, USA.
³ Medical Oncology, Royal Victoria Hospital/Cedars Cancer Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada.

PMID: 37030941
DOI: 10.1016/j.otc.2022.12.004

Abstract

Laryngeal preservation with combined modality therapy involving radiotherapy and chemotherapy is usually the treatment of choice for patients with good performance status and with locoregionally advanced laryngeal cancer with a functional larynx. Surgical management with total laryngectomy with neck dissection, followed by adjuvant radiation or chemoradiation, is recommended for patients not eligible for laryngeal preservation. This article provides an overview of the current therapeutic approaches used to treat locoregionally advanced laryngeal cancer and outlines other currently investigated therapies.

Keywords: Chemotherapy; Combined modality; Functional organ preservation; Laryngeal cancer; Locoregionally advanced; Radiotherapy.

Publication types

Review

MeSH terms

Combined Modality Therapy
Humans
Laryngeal Neoplasms* / pathology
Laryngeal Neoplasms* / therapy
Laryngectomy
Larynx* / pathology
Larynx* / surgery
Neoplasm Staging
Radiotherapy, Adjuvant
Treatment Outcome